Figure 5.

Combination of gemcitabine with PF-3758309 maximally inhibited tumour growth in vivo. TKCC 15 cells (3 × 10⁶/100 µl/site) were injected subcutaneously into the opposite flanks of 8-week old male SCID mice. On day 25 after tumour induction, when the xenografted tumours had grown to approximate 80 mm³, the mice were randomly divided into the following 5 treatment groups: control (CT), PF-3758309 (PF), gemcitabine (Gem), gemcitabine plus abraxane (Gem+Abr) and gemcitabine plus PF-3758309 (Gem+PF). Each group had 3 mice bearing 2 tumours each mouse, making 6 tumours in total. The treatments were given by intra-peritoneal (i.p.) injection for four weeks, and the mice were euthanized on day 53. The schematic diagram of tumour induction and treatment was summarized and presented (A). The tumour volume (B) and weight (C) were measured and calculated as described in Material and Methods. The average tumour volume in each group on day 25 were taken as 1 (B). The statistical significance of tumour volumes between different groups were summarized in the table (D). NS, not significant; CT, control treatment with saline; Gem, gemcitabine; PF, PF-3758309; Abr, abraxane. ##P < 0.01 compared to CT. *P < 0.05, **P < 0.01, ***P < 0.001 as indicated in the table.